Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Smoking Cessation 1Skin Neoplasms 1Prostate Cancer Prevention 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Cardiotoxicity 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × sulforaphane × Clear all
NCT04046653 2020-11-18

ADaPT

Quadram Institute Bioscience

Phase NA Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT01228084 2017-04-28

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡